PT-141 (Bremelanotide): A Research Overview

PT-141 occupies an unusual position: it is a melanocortin peptide that completed full clinical development and earned FDA approval for a specific, narrow indication — making it one of the few approved drugs in this library — while also circulating as a research compound. It is also notable for what it is derived from and engineered away from: it was refined from the tanning peptide Melanotan II to concentrate the central sexual-function effect while shedding much of that parent’s broad receptor activity. An honest overview conveys the genuine approval and clinical data, the narrowness of that approval, and the clear line between the approved product and research-grade material.

This overview summarizes what the published literature and regulatory record report about PT-141 — its structure, mechanism, evidence, approval, and safety. It describes findings as they appeared in their study populations. It is not dosing guidance, medical advice, or a recommendation for use.

What PT-141 Is

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from α-melanocyte-stimulating hormone (α-MSH) and engineered as a refined derivative of Melanotan II. It acts as a melanocortin receptor agonist, with activity primarily at the melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the brain (FDA Vyleesi prescribing information). It is the active ingredient in the FDA-approved product Vyleesi.

Mechanism — Central, Not Vascular

PT-141’s mechanism is fundamentally different from the erectile dysfunction drugs most people know. PDE5 inhibitors (Viagra, Cialis) act peripherally, on blood vessels, to support the physical arousal response. PT-141 acts centrally — on MC3R/MC4R pathways in the hypothalamus and limbic regions that govern sexual desire and arousal (Bremelanotide: First Approval, Drugs 2019). In plain terms, it targets desire in the brain rather than the vascular mechanics. This central melanocortin action is what made it a distinct approach to sexual dysfunction.

The Evidence and FDA Approval

PT-141 completed Phase III development — the RECONNECT trials — and in June 2019 was approved by the FDA as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as an as-needed subcutaneous autoinjector (FDA Vyleesi approval & Phase 3 trials (NDA 210557)). There is also published clinical literature exploring bremelanotide in male sexual dysfunction, including sildenafil-resistant erectile dysfunction (Bremelanotide development history, Drugs 2019).

Two important boundaries on that approval. First, the approval is narrow, specifically for premenopausal women with HSDD. Use in men is off-label (legal when a physician prescribes it, but outside the approved indication), and there is no separate approved “male” product (bremelanotide HSDD review (approved indication)). Second, the approval applies to the manufactured Vyleesi product, not to research-grade material sold under the PT-141 name.

• FDA-approved as Vyleesi (2019) for HSDD in premenopausal women, following Phase III RECONNECT trials.
• Acts centrally on MC3R/MC4R — a desire pathway — distinct from vascular PDE5 inhibitors.
• Use in men is off-label; research-grade PT-141 is not the approved Vyleesi product.

Safety Considerations

In its approved use, PT-141’s reported effects include nausea, flushing, headache, and injection-site reactions; transient increases in blood pressure and small changes in heart rate have been observed, so caution with blood-pressure medication is advised. Because of its melanocortin lineage, some skin or mole darkening (hyperpigmentation) can occur, though this is reduced compared with Melanotan II due to PT-141’s lower MC1R activity and intermittent (as-needed) dosing (FDA Vyleesi label (safety, BP, pigmentation)). Long-term, high-frequency safety is less well characterized than on-demand use. PT-141 should not be combined with Melanotan II — overlapping melanocortin activity amplifies effects and poses unpredictable risks.

Regulatory Status — and the Product Distinction

The status below reflects mid-2026 and may change; verify before relying on it. PT-141 is FDA-approved only as Vyleesi, by prescription, for the specific HSDD indication. Research-grade PT-141 is not the approved Vyleesi product: it is not manufactured, tested, or labeled as a finished drug, is sold for in vitro research use only, and, by its labeling, is not for human consumption. An approval for a specific product and indication does not make research-grade material safe or lawful for human use.

Why PT-141 Draws Research Interest

PT-141 is scientifically notable as the first centrally-acting melanocortin agonist approved for sexual dysfunction — a distinct pharmacological approach — and as a case study in engineering a cleaner derivative (away from Melanotan II’s broad receptor activity). The accurate framing is that an FDA-approved peptide has a narrow indication, genuine Phase III evidence, a defined safety profile, off-label use beyond its approval, and a research-grade form that must not be conflated with the approved product.

For deeper reading, the cited literature is the best starting point. PT-141 is best understood alongside its structural parent — see the Melanotan II overview — and the wider class is collected in our peptide research library.